Profound Medical Corp.
TSX:PRN.TO · Toronto Stock Exchange
+$0.11 today
Vol 0.00M · Avg 0.01M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$42.6M -53.0% | -$27.8M +1.8% | -$28.3M +1.2% | -$28.7M +6.6% | -$30.7M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $569.8K -39.1% | $936.0K -18.3% | $1.1M -28.6% | $1.6M -14.6% | $1.9M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 -100.0% | $232.0K | $0 +100.0% | -$293.0K | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $5.5M +112.7% | $2.6M -24.5% | $3.4M -19.4% | $4.2M -41.2% | $7.2M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$1.7M -394.9% | $591.0K +9.4% | $540.0K +109.6% | -$5.6M -541.8% | -$877.0K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$175.0K -194.1% | $186.0K +113.2% | -$1.4M +26.7% | -$1.9M -196.6% | $2.0M | $592.6M | $1.3B | $626.2M |
| Inventory | -$2.9M -537.7% | $656.0K +85.8% | $353.0K +118.9% | -$1.9M +25.2% | -$2.5M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $384.6K -52.8% | $815.0K -39.9% | $1.4M +339.6% | -$566.0K -59.0% | -$356.0K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $918.8K +186.2% | -$1.1M -536.9% | $244.0K +119.2% | -$1.3M -4788.4% | -$26.0K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$622.6K -344.2% | $255.0K -32.7% | $379.0K -85.7% | $2.7M +524.9% | $425.0K | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$38.9M -65.8% | -$23.5M -3.7% | -$22.6M +12.4% | -$25.8M -15.4% | -$22.4M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$179.1K | $0 | $0 | $0 +100.0% | -$593.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$246.2K | $0 | $0 | $0 +100.0% | -$583.0K | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$1.3M +48.1% | -$2.6M -112.6% | -$1.2M -117.4% | $6.9M +1892.0% | -$386.0K | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $43.2M -30.5% | $62.1M +2190.7% | $2.7M +962.5% | $255.2K -96.0% | $6.3M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 +100.0% | -$4.8M -2049.8% | $248.7K +276.2% | -$141.2K -1663.7% | $9.0K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $41.9M -23.5% | $54.7M +3014.8% | $1.8M -75.0% | $7.0M +18.2% | $5.9M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$630.9K +75.2% | -$2.5M -563.4% | $549.0K +129.4% | -$1.9M -864.8% | $244.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $2.1M -92.7% | $28.7M +241.3% | -$20.3M +1.6% | -$20.6M -23.1% | -$16.8M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$39.1M -66.5% | -$23.5M -5.2% | -$22.3M +13.6% | -$25.8M -12.4% | -$23.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
NervGen Pharma Corp.
NGEN.V
$407.94M
Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO
$325.95M
Medical Facilities Corporation
TSX:DR.TO
$315.55M
Auxly Cannabis Group Inc.
TSX:XLY.TO
$250.54M
Quipt Home Medical Corp.
QIPT.TO
$221.44M
CareRx Corporation
TSX:CRRX.TO
$203.03M
Cybin Inc.
CYBN.NE
$154.92M
HLS Therapeutics Inc.
TSX:HLS.TO
$133.86M
Jushi Holdings Inc.
JUSH.CN
$133.80M
VentriPoint Diagnostics Ltd.
VPT.V
$22.52M
SEC Filings
Recent regulatory filings
No filings found.
Does PRN.TO generate free cash flow?
Profound Medical Corp. (PRN.TO) generated -$39,054,917.00 of free cash flow in fiscal 2025.
How much operating cash flow does PRN.TO produce?
Operating cash flow was -$38,875,833.00, before capital expenditures of $179,083.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.